|Mr. Patrick J. McEnany||Co-Founder, Chairman, Pres & CEO||856.3k||N/A||1947|
|Dr. Steven R. Miller||COO & Chief Scientific Officer||608.92k||N/A||1962|
|Dr. Gary Ingenito||Chief Medical Officer & Head of Regulatory Affairs||620.38k||N/A||1956|
|Ms. Alicia Grande||VP, Treasurer & CFO||N/A||N/A||1971|
|Mr. Brian Elsbernd||Chief Legal & Compliance Officer||N/A||N/A||1964|
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 7.